Microglial activation and progressive brain changes in schizophrenia

Liliana Laskaris, Maria A Di Biase, Ian Paul Everall, Gursharan Chana, Arthur Christopoulos, Efstratios Stan Skafidas, Vanessa L Cropley, Christos Pantelis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.
Original languageEnglish
Pages (from-to)666-680
Number of pages15
JournalBritish Journal of Pharmacology
Volume173
Issue number4
DOIs
Publication statusPublished - 2016

Cite this

Laskaris, L., Di Biase, M. A., Everall, I. P., Chana, G., Christopoulos, A., Skafidas, E. S., ... Pantelis, C. (2016). Microglial activation and progressive brain changes in schizophrenia. British Journal of Pharmacology, 173(4), 666-680. https://doi.org/10.1111/bph.13364
Laskaris, Liliana ; Di Biase, Maria A ; Everall, Ian Paul ; Chana, Gursharan ; Christopoulos, Arthur ; Skafidas, Efstratios Stan ; Cropley, Vanessa L ; Pantelis, Christos. / Microglial activation and progressive brain changes in schizophrenia. In: British Journal of Pharmacology. 2016 ; Vol. 173, No. 4. pp. 666-680.
@article{213d228bcb31409fae19b029b62621aa,
title = "Microglial activation and progressive brain changes in schizophrenia",
abstract = "Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.",
author = "Liliana Laskaris and {Di Biase}, {Maria A} and Everall, {Ian Paul} and Gursharan Chana and Arthur Christopoulos and Skafidas, {Efstratios Stan} and Cropley, {Vanessa L} and Christos Pantelis",
year = "2016",
doi = "10.1111/bph.13364",
language = "English",
volume = "173",
pages = "666--680",
journal = "British Journal of Pharmacology",
issn = "1476-5381",
publisher = "Wiley-Blackwell",
number = "4",

}

Laskaris, L, Di Biase, MA, Everall, IP, Chana, G, Christopoulos, A, Skafidas, ES, Cropley, VL & Pantelis, C 2016, 'Microglial activation and progressive brain changes in schizophrenia', British Journal of Pharmacology, vol. 173, no. 4, pp. 666-680. https://doi.org/10.1111/bph.13364

Microglial activation and progressive brain changes in schizophrenia. / Laskaris, Liliana; Di Biase, Maria A; Everall, Ian Paul; Chana, Gursharan; Christopoulos, Arthur; Skafidas, Efstratios Stan; Cropley, Vanessa L; Pantelis, Christos.

In: British Journal of Pharmacology, Vol. 173, No. 4, 2016, p. 666-680.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Microglial activation and progressive brain changes in schizophrenia

AU - Laskaris, Liliana

AU - Di Biase, Maria A

AU - Everall, Ian Paul

AU - Chana, Gursharan

AU - Christopoulos, Arthur

AU - Skafidas, Efstratios Stan

AU - Cropley, Vanessa L

AU - Pantelis, Christos

PY - 2016

Y1 - 2016

N2 - Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.

AB - Schizophrenia is a debilitating disorder that typically begins in adolescence and is characterized by perceptual abnormalities, delusions, cognitive and behavioural disturbances and functional impairments. While current treatments can be effective, they are often insufficient to alleviate the full range of symptoms. Schizophrenia is associated with structural brain abnormalities including grey and white matter volume loss and impaired connectivity. Recent findings suggest these abnormalities follow a neuroprogressive course in the earliest stages of the illness, which may be associated with episodes of acute relapse. Neuroinflammation has been proposed as a potential mechanism underlying these brain changes, with evidence of increased density and activation of microglia, immune cells resident in the brain, at various stages of the illness. We review evidence for microglial dysfunction in schizophrenia from both neuroimaging and neuropathological data, with a specific focus on studies examining microglial activation in relation to the pathology of grey and white matter. The studies available indicate that the link between microglial dysfunction and brain change in schizophrenia remains an intriguing hypothesis worthy of further examination. Future studies in schizophrenia should: (i) use multimodal imaging to clarify this association by mapping brain changes longitudinally across illness stages in relation to microglial activation; (ii) clarify the nature of microglial dysfunction with markers specific to activation states and phenotypes; (iii) examine the role of microglia and neurons with reference to their overlapping roles in neuroinflammatory pathways; and (iv) examine the impact of novel immunomodulatory treatments on brain structure in schizophrenia.

UR - http://onlinelibrary.wiley.com.ezproxy.lib.monash.edu.au/doi/10.1111/bph.13364/epdf

U2 - 10.1111/bph.13364

DO - 10.1111/bph.13364

M3 - Article

VL - 173

SP - 666

EP - 680

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 1476-5381

IS - 4

ER -